| Quantity: | |
|---|---|
【COMPOSITION AND CONTENT】
This product contains inactivated Newcastle Disease Virus Strain La Sota and inactivated H9 Subtype Avian Influenza Virus Strain HL. Before inactivation, the viral titer of both strains is no less than 2×10⁸·⁰ EID₅₀ per 0.1 mL.
【CHARACTER】
White homogeneous emulsion
【INDICATIONS】
For the prevention of Newcastle disease and H9 subtype avian influenza in chickens. The immune duration lasts 4 months.
【DOSAGE AND ADMINISTRATION】
Administer via subcutaneous or intramuscular injection. 0.3 mL per chicken for chickens aged 2 to 5 weeks; 0.5 mL per bchicken for chickens aged over 5 weeks.
【PRESENTATION】
100 mL/bottle, 250 mL/bottle, 500 mL/bottle
【STORAGE AND SHELF LIFE】
Store at 2–8 °C. Shelf life: 12 months from the date of manufacture.
For use only under veterinary supervision.
1. Dual-strain precise compounding for dual-disease prevention: Compounded with classic La Sota strain and H9 subtype avian influenza HL strain, the vaccine accurately targets mainstream epidemic strains in domestic chicken farms. It prevents both Newcastle disease and H9 avian influenza with one injection, simplifying immunization procedures and reducing repeated vaccination stress and costs.
2. Ultra-high virus titer ensures powerful and sufficient immune reserve: Both strains maintain ultra-high virus titer before inactivation, with sufficient and pure antigen reserve. It strongly stimulates the production of high-level and uniform protective antibodies, builds a solid immune barrier, and effectively reduces the risk of wild virus infection and mixed infection.
3. Fully inactivated safe process with zero virus diffusion and low stress: Adopting mature complete inactivation technology, the vaccine has no live virus residue or strain reversion risk. It causes no adverse reactions to chicken flocks, does not affect growth and production performance, and ensures safe daily immunization for all healthy chickens.
4. Age-based segmented dosage adapts to chickens at all stages: Scientific differentiated dosage matches the physiological characteristics of young and adult chickens. The graded dosage ensures standardized and balanced immune protection for flocks of different ages, avoiding insufficient protection or vaccine waste.
5. Stable emulsion formulation for durable antibody protection: The uniform milky white emulsion features stable texture without delamination or emulsion breakage. The sustained-release antigen stimulates long-term antibody production after injection, achieving a fixed 4-month immune duration and stable epidemic prevention protection.
6. Dual flexible vaccination methods adapt to full breeding scenarios: Supports both intramuscular and subcutaneous injection with minimal trauma and fast recovery. It adapts to the operation habits and breeding modes of all-scale chicken farms, with strong on-site practicability for batch immunization.
Q: What type of vaccine is this? What diseases does it prevent?
A: This is a dual inactivated vaccine for Newcastle disease and H9 subtype avian influenza, a non-prescription veterinary drug. It is specially used to prevent chicken Newcastle disease and H9 avian influenza, serving as the core basic vaccine for poultry respiratory disease prevention.
Q: What are the core advantages and protection characteristics of the vaccine?
A: The vaccine realizes labor-saving dual disease prevention with high-titer dual antigens. Featuring full-inactivation safety, age-based precise dosage, stable emulsion and 4-month fixed protection duration, it is easy to operate and highly suitable for daily epidemic prevention of large-scale poultry farms.
Q: What are the applicable chickens, vaccination method and standard dosage?
A: Applicable to healthy chickens of all breeds via subcutaneous or intramuscular injection. The dosage is 0.3mL per chicken for 2–5-week-old birds and 0.5mL per chicken for birds over 5 weeks old to ensure qualified immune efficacy.
Q: What is the usage time limit for opened vaccine?
A: The vaccine must be completely used up on the opening day to avoid antigen attenuation and immune failure. Overnight residual vaccine is prohibited for use.
